Kevin Röhle

Title: Kevin Röhle: Innovator in Immunotherapy

Introduction

Kevin Röhle is a prominent inventor based in Tuebingen, Germany. He has made significant contributions to the field of immunotherapy, particularly in the development of peptides for cancer treatment. With a total of two patents to his name, Röhle is recognized for his innovative approaches to combating ovarian cancer and other malignancies.

Latest Patents

Röhle's latest patents focus on peptides and combinations of peptides for use in immunotherapy against ovarian cancer and other cancers. The inventions relate to peptides, proteins, nucleic acids, and cells utilized in immunotherapeutic methods. Specifically, these patents address the immunotherapy of cancer by introducing tumor-associated T-cell peptide epitopes. These epitopes can serve as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses. Additionally, they can be used to stimulate T cells ex vivo and transfer them into patients. The peptides can also be bound to molecules of the major histocompatibility complex (MHC) or serve as targets for antibodies and other binding molecules.

Career Highlights

Kevin Röhle is currently associated with Immatics Biotechnologies GmbH, where he continues to advance his research in immunotherapy. His work is pivotal in the ongoing fight against cancer, and he is dedicated to developing effective treatment options for patients.

Collaborations

Röhle collaborates with notable colleagues, including Heiko Schuster and Hans-Georg Rammensee. Their combined expertise contributes to the innovative research and development efforts at Immatics Biotechnologies GmbH.

Conclusion

Kevin Röhle is a key figure in the field of immunotherapy, with a focus on developing peptide-based treatments for cancer. His contributions are vital to advancing cancer treatment and improving patient outcomes.